Skip to main content
SpringerLink
Log in

Medikamente zur Behandlung von Persönlichkeits- und Verhaltensstörungen

  • Chapter
Kompendium der Psychiatrischen Pharmakotherapie

  • 5878 Accesses

Zusammenfassung

Die Behandlung von Persönlichkeits- und Verhaltensstörungen ist zur Domäne der Psychotherapie geworden. Gleichwohl hat die Psychopharmakotherapie insbesondere im Klinikalltag einen hohen Stellenwert. Einige Verhaltensstörungen werden aufgrund der neuen DSM-5-Strukturen in anderen Kapiteln besprochen, z. B. die Verhaltenssüchte in Kapitel 7.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Amad A, Thomas P, Perez-Rodriguez MM (2015) Borderline personality disorder and oxytocin: review of clinical trials and future directions. Curr Pharm Des 21: 3311–3316

    Article  CAS  Google Scholar 

  • Bellino S, Bozzatello P, Rocca G et al (2014) Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. J Psychopharmacol 28: 125–132

    Article  Google Scholar 

  • Black DW, Zanarini MC, Romine A et al (2014) Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 171: 1174–1182

    Article  Google Scholar 

  • Bolm T (2015) Therapie der Borderline-Persönlichkeitsstörung. DNP – Der Neurologe & Psychiater 16: 34–37

    Article  Google Scholar 

  • Bozzatello P, Brignolo E, De Grandi E, Bellino S (2016) Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data. J Clin Med 5(8): pii: E67

    Google Scholar 

  • Bozzatello P, Rocca P, Bellino S (2018) Combination of omega-3 fatty acids and valproic acid in treatment of borderline personality disorder: a follow-up study. Clin Drug Investig 38(4): 367–372

    Article  CAS  Google Scholar 

  • Bridler R, Häberle A, Müller ST et al (2015) Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders. Eur Neuropsychopharmacol 25: 763–772

    Article  CAS  Google Scholar 

  • Brüne M (2015) On the role of oxytocin in borderline personality disorder. Br J Clin Psychol 55(3): 287–304

    Article  Google Scholar 

  • Costa AM, Medeiros GC, Redden S et al (2018) Cognitive-behavioral group therapy for intermittent explosive disorder: description and preliminary analysis. Rev Bras Psiquiatr 40(3): 316–319

    Article  Google Scholar 

  • Crawford MJ, Sanatinia R, Barrett B et al; LABILE study team (2018) The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. Am J Psychiatry 175(8): 756–764

    Google Scholar 

  • Cristea IA, Gentili C, Cotet CD et al (2017) Efficacy of psychotherapies for borderline personality disorder: a systematic review and meta-analysis. JAMA Psychiatry 74(4): 319–328

    Article  Google Scholar 

  • Falkai P, Wittchen HU (Hrsg) (2015) DSM-5. Diagnostisches und Statistisches Manual Psychischer Störungen. Hogrefe, Göttingen

    Google Scholar 

  • Farde L, Plavén-Sigray P, Borg J, Cervenka S (2018) Brain neuroreceptor density and personality traits: towards dimensional biomarkers for psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 373(1744): pii: 20170156

    Article  Google Scholar 

  • Gunderson JG, Stout RL, McGlashan TH et al (2011) Ten-year course of borderline personality disorder. Arch Gen Psychiatry 68: 827–837

    Article  Google Scholar 

  • Hancock-Johnson E, Griffiths C, Picchioni M (2017) A focused systematic review of pharmacological treatment for borderline personality disorder. CNS Drugs 31(5): 345–356

    Article  CAS  Google Scholar 

  • Herpertz SC (2018) Neue Wege der Klassifikation von Persönlichkeitsstörungen in ICD-11. Fortschr Neurol Psychiatr 86(03): 150–155

    Article  Google Scholar 

  • Herpertz SC, Bertsch K (2015) A new perspective on the pathophysiology of borderline personality disorder: a model of the role of oxytocin. Am J Psychiatry 172: 840–851

    Article  Google Scholar 

  • Ingenhoven TJ, Duivenvoorden HJ (2011) Differential effectiveness of antipsychotics in borderline personality disorder: meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains. J Clin Psychopharmacol 31(4): 489–496

    Article  CAS  Google Scholar 

  • Ingenhoven T, Lafay P, Rinne T et al (2010) Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry 71: 14–25

    Article  Google Scholar 

  • Krüger TH, Magid M, Wollmer MA (2016) Can botulinum toxin help patients with borderline personality disorder? Am J Psychiatry 173(9): 940–941

    Article  Google Scholar 

  • Lischke A, Herpertz SC, Berger C (2017) Divergent effects of oxytocin on (para-)limbic reactivity to emotional and neutral scenes in females with and without borderline personality disorder. Soc Cogn Affect Neurosci 12(11): 1783–1792

    Article  Google Scholar 

  • Martín-Blanco A, Patrizi B, Soler J et al (2017a) Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder: a preliminary report. Int Clin Psychopharmacol 32(4): 231–234

    Article  Google Scholar 

  • Martín-Blanco A, Ancochea A, Soler J et al (2017b) Changes over the last 15 years in the psychopharmacological management of persons with borderline personality disorder. Acta Psychiatr Scand 136(3): 323–331

    Article  Google Scholar 

  • Mielke EL, Neukel C, Bertsch K et al (2018) Alterations of brain volumes in women with early life maltreatment and their associations with oxytocin. Horm Behav 97: 128–136

    Article  CAS  Google Scholar 

  • Naguy A, Al-Enezi N (2017) Lamotrigine uses in psychiatric practice-beyond bipolar prophylaxis a hope or hype? Am J Ther [Epub ahead of print]

    Google Scholar 

  • Pérez-Pérez B, Cristóbal-Narváez P, Sheinbaum T et al (2018) Interaction between FKBP5 variability and recent life events in the anxiety spectrum: evidence for the differential susceptibility model. PLoS One 13(2): e0193044

    Article  Google Scholar 

  • Schwerthöffer D, Bäuml J, Rentrop M (2013) Pharmakotherapie der Borderline-Störung: Praxis und Studienlage. Fortschr Neurol Psychiatr 81: 437–443

    Article  Google Scholar 

  • Stoffers J, Völlm BA, Rücker G et al (2010) Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev 6: CD005653

    Google Scholar 

  • Stoffers JM, Völlm BA, Rücker G et al (2012) Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev: CD005652

    Google Scholar 

  • Stoffers-Winterling J, Lieb K (2015) Pharmakotherapie von Borderline-Persönlichkeitsstörungen – Versorgungsalltag versus aktuelle externe Evidenz. Info Neurol Psychiatrie 17: 51–55

    Article  Google Scholar 

  • Tebartz van Elst L, Fleck M, Bartels S et al (2016) Increased prevalence of intermittent rhythmic delta or theta activity (IRDA/IRTA) in the electroencephalograms (EEGs) of patients with borderline personality disorder. Front Behav Neurosci 10: 12

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Berlin, Deutschland

    Prof. Dr. med. Dr. rer. nat. Dipl.-Psych. M. J. Müller

  2. Mainz, Deutschland

    Prof. Dr. med. O. Benkert

Authors
  1. Prof. Dr. med. Dr. rer. nat. Dipl.-Psych. M. J. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. O. Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to M. J. Müller or O. Benkert .

Editor information

Editors and Affiliations

  1. Mainz, Deutschland

    O. Benkert

  2. München, Deutschland

    H. Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag GmbH Deutschland

About this chapter

Cite this chapter

Müller, M.J., Benkert, O. (2019). Medikamente zur Behandlung von Persönlichkeits- und Verhaltensstörungen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57334-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-57334-1_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-57333-4

  • Online ISBN: 978-3-662-57334-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation